Clinical Trials | June 23, 2026
Pfizer lung cancer drug misses key survival goal in Phase 3 trial
The company said the safety profile remained consistent with earlier studies and was considered manageable
The company said the safety profile remained consistent with earlier studies and was considered manageable
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Clara Sattler de Sousa e Brito to lead discovery solutions from Q3 2026, while Robert Machinek takes over as Head of Strategy & Business Development
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Veteran healthcare leader to oversee operations across Tamil Nadu and Kerala, driving growth and operational excellence
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
